|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 247.90 DKK | -0.30% |
|
+4.20% | -23.78% |
| 01:22am | Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports | RE |
| 12:57am | Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports | RE |
| Capitalization | 1,102B 171B 147B 133B 128B 233B 15,715B 244B 1,573B 630B 7,536B 642B 628B 26,953B | P/E ratio 2026 * |
11.7x | P/E ratio 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 1,210B 188B 162B 146B 140B 256B 17,267B 268B 1,729B 693B 8,280B 705B 690B 29,614B | EV / Sales 2026 * |
4.25x | EV / Sales 2027 * | 4.02x |
| Free-Float |
70.25% | Yield 2026 * |
4.35% | Yield 2027 * | 4.55% |
Last Transcript: Novo Nordisk A/S
| 1 day | -0.30% | ||
| 1 week | +4.20% | ||
| Current month | +4.20% | ||
| 1 month | -16.11% | ||
| 3 months | -19.93% | ||
| 6 months | -29.17% | ||
| Current year | -23.78% |
| 1 week | 224.25 |  | 255.25 |
| 1 month | 224.25 | | 321.95 |
| Current year | 224.25 | | 409.95 |
| 1 year | 224.25 | | 605.5 |
| 3 years | 224.25 | | 1,033.2 |
| 5 years | 210.08 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 06/08/2025 | |
| Director of Finance/CFO | 55 | 14/02/2018 | |
Martin Lange
CTO | Chief Tech/Sci/R&D Officer | 56 | 06/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kasim Kutay
BRD | Director/Board Member | 61 | 22/03/2017 |
| Director/Board Member | 51 | 21/03/2018 | |
| Director/Board Member | 61 | 23/03/2022 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.51% | 21.31% | 1,387 M€ | |
| +0.29% | 10.45% | 4 M€ | |
| -1.01% | 5.4% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.30% | +4.20% | -59.52% | -50.81% | 171B | |
| +0.72% | -5.86% | +8.50% | +210.49% | 878B | |
| +0.32% | -3.23% | +44.97% | +54.54% | 577B | |
| -0.96% | -0.85% | +9.19% | +48.19% | 411B | |
| -2.93% | -7.03% | +12.72% | +26.04% | 359B | |
| -1.85% | -6.70% | +20.55% | +34.98% | 305B | |
| -1.25% | -5.55% | +23.92% | +55.59% | 304B | |
| -0.24% | -6.49% | +23.18% | +4.22% | 287B | |
| +0.53% | -4.80% | +16.27% | +57.17% | 198B | |
| -0.83% | -3.37% | +24.03% | +77.45% | 180B | |
| Average | -0.68% | -3.13% | +12.38% | +51.79% | 367.05B | |
| Weighted average by Cap. | -0.47% | -3.58% | +16.17% | +79.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 285B 44.24B 38.15B 34.43B 33.04B 60.25B 4,066B 63.05B 407B 163B 1,950B 166B 163B 6,973B | 300B 46.52B 40.11B 36.21B 34.74B 63.35B 4,275B 66.3B 428B 171B 2,050B 175B 171B 7,332B |
| Net income | 94.01B 14.59B 12.58B 11.36B 10.9B 19.87B 1,341B 20.8B 134B 53.79B 643B 54.77B 53.6B 2,300B | 94.58B 14.68B 12.66B 11.43B 10.96B 19.99B 1,349B 20.92B 135B 54.12B 647B 55.1B 53.93B 2,314B |
| Net Debt | 109B 16.88B 14.56B 13.14B 12.61B 22.99B 1,552B 24.06B 155B 62.24B 744B 63.37B 62.02B 2,661B | 102B 15.88B 13.69B 12.36B 11.86B 21.63B 1,460B 22.63B 146B 58.54B 700B 59.61B 58.33B 2,503B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 247.90 kr | -0.30% | 6,430,038 |
| 05/03/26 | 248.65 kr | +1.30% | 6,130,778 |
| 04/03/26 | 245.45 kr | +6.03% | 7,277,512 |
| 03/03/26 | 231.50 kr | -2.34% | 13,000,450 |
| 02/03/26 | 237.05 kr | -0.36% | 8,389,428 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition